| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H24N2O3 |
| Molecular Weight | 292.3734 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NC[C@@H](O)COC1=C2CCC(=O)NC2=CC=C1
InChI
InChIKey=LWAFSWPYPHEXKX-LLVKDONJSA-N
InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)/t11-/m1/s1
| Molecular Formula | C16H24N2O3 |
| Molecular Weight | 292.3734 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
(R)-Carteolol is an enantiomer of the drug carteolol that is used to treat glaucoma. (R)-Carteolol is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage of the R(+)-isomers is similar to the S(-)-isomers and there is no stereoselectivity between the two enantiomers.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
